Alector's Alzheimer’s Phase II Failure Leads to 17% Workforce Reduction and Strategic Shift

Alector's experimental Alzheimer's drug, AL002, failed to achieve the desired outcomes in its Phase II INVOKE-2 trial. The study did not meet its primary efficacy endpoint, nor did it result in improvements in secondary outcomes or biomarkers, and raised safety concerns due to amyloid-related imaging abnormalities and infusion reactions. As a result of this setback, Alector has decided to discontinue further studies of AL002 and undergo a significant strategic shift, including a workforce reduction of 17%, affecting approximately 41 employees[1][2][3]. This failure in the Phase II trial has led to a realignment of resources and a strategic refocus on other programs, such as the company’s frontotemporal dementia candidate AL001, and further exploration of its blood-brain-barrier platform [1][2].